Moderna Future Growth

Future criteria checks 2/6

Moderna is forecast to grow earnings and revenue by 67.6% and 20.6% per annum respectively. EPS is expected to grow by 66.7% per annum. Return on equity is forecast to be -4.9% in 3 years.

Key information

67.6%

Earnings growth rate

66.7%

EPS growth rate

Biotechs earnings growth24.6%
Revenue growth rate20.6%
Future return on equity-4.9%
Analyst coverage

Good

Last updated13 Jun 2024

Recent future growth updates

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Recent updates

What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Jun 06
What Moderna, Inc.'s (NASDAQ:MRNA) 27% Share Price Gain Is Not Telling You

Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor

May 23

Moderna Q1: A Promising Pipeline Is Undervalued

May 15

We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Apr 30
We Discuss Why Moderna, Inc.'s (NASDAQ:MRNA) CEO Compensation May Be Closely Reviewed

Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Apr 22
Moderna, Inc.'s (NASDAQ:MRNA) Prospects Need A Boost To Lift Shares

Moderna: Considering The Cancer Vaccine Angle

Apr 11

Moderna Continues To Build A Pipeline

Apr 03

Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play

Mar 27

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29
Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Nov 03
Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Oct 18
Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Earnings and Revenue Growth Forecasts

NasdaqGS:MRNA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266,554-493-1,227-44717
12/31/20254,844-2,017-2,015-1,45423
12/31/20244,167-2,680-2,321-1,70223
3/31/20245,153-5,968-3,672-2,882N/A
12/31/20236,848-4,714-3,825-3,118N/A
9/30/20239,121-3,466-2,657-2,078N/A
6/30/202310,6541,207-754-226N/A
3/31/202315,0594,784612993N/A
12/31/202219,2638,3624,5814,981N/A
9/30/202221,39011,7656,2016,629N/A
6/30/202222,99514,0559,2159,653N/A
3/31/202222,60014,63813,03113,412N/A
12/31/202118,47112,20213,33613,620N/A
9/30/202111,8317,06111,38611,574N/A
6/30/20217,0193,4959,0839,191N/A
3/31/20212,7325985,0075,104N/A
12/31/2020803-7471,9592,027N/A
9/30/2020246-597613664N/A
6/30/2020106-488-374-336N/A
3/31/202052-505-451-421N/A
12/31/201960-514-491-459N/A
9/30/201982-535-489-451N/A
6/30/2019106-499-482-424N/A
3/31/2019122-459-445-364N/A
12/31/2018135-402-437-331N/A
9/30/2018192-299-447-343N/A
6/30/2018192-280-412-305N/A
3/31/2018199-266-432-350N/A
12/31/2017206-270N/A-331N/A
12/31/2016108-230N/A67N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRNA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MRNA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MRNA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MRNA's revenue (20.6% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: MRNA's revenue (20.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MRNA is forecast to be unprofitable in 3 years.


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.